Efficacy of the Combination of Venetoclax and Azacitidine in Elderly of Frail Relapsed/ Refractory Patients with Acute Myeloid Leukemia, First Multi-Institutional Real World Experience from Turkey

Author:

AKTIMUR SUDE HATUN

Abstract

Acute myeloid leukemia (AML) usually seen in the elderly. The quest for effective, tolerable and durable response for the treatment of elderly or frail patients with AML resulted venetoclax combination. The aim of this study was to present here the experience and data for the use of venetoclax in combination with azacitidine in elderly or frail and unfit patients with relapse/refractory AML treated outside of a clinical trial. We retrospectively analyzed 30 consecutive elderly (≥ 65 years old) or frail patients with relapse/refractory AML, who failed at least one prior therapy for AML and treated with venetoclax in combination with 5-azacitidine at five institutions in Turkey between December 2018 - Januarry 2020. The patients were taken venetoclax at dose of 400 mg daily, and 75 mg/m2/day azacitidine subcutaneously for 7 days per 28-day cycle. Complete remission (CR), incomplete blood count recovery (CRi), PR, overall survival (OS) and event free survival (EFS) were assessed. A total of 30 patients with a median age of 67 (range= 33-84) from 5 differ- ent centers were included in the final analysis. Overall response rate (ORR) was 63.3% (n= 19); 15 (50%) patients achieved CR or CRi and 4 (13.3%) patients achieved PR while 11 patients (37.7%) did not respond to therapy. Median 8 months follow-up, 6 months OS rate 66.7%, 1-year OS rate was 19.8% with a median OS was 7 months (95% CI: 7.8 -10.1). The mortality risk of patients under 60 is statistically significantly lower than those over 60 (p= 0.007, HR: 0.109 (95% CI: 0.022 - 0.55). Combination of venetoclax + HMA in patients with relapse refractory AML with poor performance score, it provided somewhat higher response rates and additionally, the responding patients benefited surival advantage when compared to non-responding patients. Keywords: AML, Elderly, Venetoclax, Azacitidine, Survival

Publisher

Akademi Doktorlar Yayinevi

Subject

Oncology,Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3